30th ASNTR annual conference 2023

30th ASNTR annual conference 2023

Celebrating Thirty Years of Developing
Neural Therapies and Repair

The American Society for Neural Therapy and Repair (ASNTR) will be holding the 2023 meeting in the beautiful location of Clearwater Beach, Florida, USA on April 27 – 30th.

Check the website, program and registration details to follow: https://www.asntr.org/

NECTAR 2022 Meeting News

NECTAR 2022 Meeting News

As president of NECTAR and on behalf of Rebecca Matsas & the local organising committee we would like to thank all presenters and participants for making our NECTAR 2022 conference a great success! The quality of the work presented here was outstanding and the variety of subjects much appreciated. This was the first time that a NECTAR meeting was held in the beautiful city of Athens. With 125 registered attendees, mostly in person, and a great venue, discussions and new collaborations are bound to carry on for several months.

We would also like to thank our sponsors for making this event possible and renewing their support to our network.

Please use the link below in order to download the meeting booklet.

https://az659834.vo.msecnd.net/eventsairwesteuprod/production-era-public/703c05e57196404e93dff17769378efe

And if you could not attend this NECTAR meeting, we are already looking forward to seeing you and hearing about your work in 2023!

3rd APANTR Meeting

3rd APANTR Meeting

 

This one-day meeting will bring together a range of clinical and basic neuroscience. Hosted in Hobart, our program will include presentations from a range of senior and early career researchers. Meeting includes a full day program including lunch and a networking event in the evening.

DATE: 14th October 2022

TIME: 10am-5:30pm and an evening networking event

LOCATION: The Menzies Institute for Medical Research, Hobart, Tasmania, Australia

REGISTER HERE

COST: FREE

SUBMISSION FOR DATABLITZ OPEN NOW

Presenting data as a datablitz is a great opportunity for ECRs to showcase their work. The format this year will be 3min talk + 2min questions.

To apply, send a 250 word abstract and title to apantr.secretariat@outlook.com by COB 30th September.

Drivers Seat Talks series

Drivers Seat Talks series

Lund University has launched a new series of Zoom-based seminars.

The format
In the weekly “Drivers Seat Talks” the people that have driven a study will present their work in a  zoom-based online Journal Club format. The idea is a 20-30 minute presentation going through a recently published article followed by a personal account of the main achievements and struggles conducting the experiments that have lead to the publication. The presentation will include the main figures of the selected paper and conclude with a slide on the major roadblocks that were encountered.

The topics
Topics will be very varied, including neuroscience, from disease modelling, stem cells, gene therapy, to technological advances and everything in between.

How
Tuesdays 17:00 CEST
online: zoom room 630 8461 5083
speaker list: http://www.driverseattalks.com/schedule.html
Twitter: @driverseattalks

Welcome Romina Aron Badin as new NECTAR president

Welcome Romina Aron Badin as new NECTAR president

Based on a unanimous board decision, we are pleased to announce that we can now welcome the new president of NECTAR: Dr. Romina Aron Badin! Romina is the associate director of the Molecular Imaging Research Center (MIRCen) at the CEA center in Paris, and is an expert in in vivo preclinical imaging of animal models, including work on several Parkinson’s and Huntington’s disease transplantation studies in rodents and primates. Romina has been an active member of the NECTAR board for several years and was the main organiser of the NECTAR meeting in Paris, 2018. We are very grateful and delighted that Romina has accepted to take on the task as President for NECTAR. As outgoing President, Agnete Kirkeby sends a heartfelt “Thank you!” to the board, the meeting organisers and all the members of the network for making the past 2 years of NECTAR a joyful and highly scientifically inspiring experience.

Contact details:

romina.aron-badin@cea.fr

18 route du Panorama,

92265 Fontenay-aux-Roses,

France

Tel: +33 146548529

Fax: +33 146548451

Episode 1, 2 AND 3 of the NECTAR 2021 podcast available

Episode 1, 2 AND 3 of the NECTAR 2021 podcast available

Episode 1-3 of the NECTAR 2021 podcast are available!

Episode 1 by Anders Björklund and Stephen Dunnett
To open the podcast, please go to:  https://media.ed.ac.uk/media/1_s7q3rncy
You’re also welcome to open the transcript of the interview.

Episode 2 by Tilo Kunath
To open the podcast, please go to:  https://media.ed.ac.uk/media/1_vm7s9r6b
You’re also welcome to open the transcript of the interview.

Episode 3 by Lana Zholudeva and Michael Lane
To open the podcast, please go to: https://media.ed.ac.uk/media/1_5ytngxk3
You’re also welcome to open the transcript of the interview.

Tom Isaacs Special Issue

Tom Isaacs Special Issue

We are delighted to let you know that the European Journal of Neuroscience, NECTAR and the Cure Parkinson’s Trust Special Issue dedicated to Tom Isaacs will be published online on 8th of February and published in print on the 20th of February. The final list of articles is here:

  1. In Memory of Tom Isaacs: The Epitomical Mover and Shaker” by Lyndsey Isaacs, Roger Barker and Eilís Dowd.
  2. The Power of the Parkinson’s Patient According to Tom Isaacs: A Call to Action” by Soania Mathur.
  3. The Linked Clinical Trials Initiative (LCT) for Parkinson’s disease” by Patrik Brundin and Richard Wyse.
  4.  Genetically engineered stem cell‐derived neurons can be rendered resistant to alpha‐synuclein aggregate pathology” by Patrik Brundin and Gerhard Coetzee.
  5. The Prodromes of Parkinson’s disease” by Richard Rees, Alastair Noyce and Anette Schrag.
  6. “The clinical heterogeneity of Parkinson’s disease and its therapeutic implications” by Julia Greenland, Caroline Williams‐Grayand Roger A. Barker.
  7. The Unlikely Partnership Between LRRK2 and α-Synuclein in Parkinson’s Disease” by Andrew West, Emmanuel Brouillet and colleagues.
  8. Immune system responses in Parkinson’s disease: early and dynamic” by Malú Tansey and Marina Romero-Ramos.
  9. L-DOPA for Parkinson’s disease – a bittersweet pill” by Emma Lane.
  10. Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?” by Susan Fox and Jonathan Brotchie.
  11. Post hoc analysis of the Exenatide-PD trial – factors that predict response” by Tom Foltynie and colleagues.
  12. Mitral cells and the glucagon-like peptide 1 receptor: The sweet smell of success?” by Enrico Bagnoli and Una Fitzgerald.
  13. Trophic factors for Parkinson’s disease: Where are we and where do we go from here?” by Gesine Paul and Aideen Sullivan.
  14. Are PARKIN patients ideal candidates for dopaminergic cell replacement therapies?” by Tilo Kunathand colleagues.
  15. Cell-based therapy for Parkinson’s disease: A journey through decades toward the light side of the Force” by Malin Parmar, Olof Torper and Janelle Drouin‐Ouellet.
  16. Primary tissue for cellular brain repair in Parkinson’s disease: Promise, problems and the potential of biomaterials” by Niamh Moriarty, Clare Parish and Eilís Dowd.
  17. Encapsulation of young donor age dopaminergic grafts in a GDNF-loaded collagen hydrogel further increases their survival, reinnervation, and functional efficacy after intrastriatal transplantation in hemi-Parkinsonian rats” by Eilís Dowd and colleagues.
  18. Non-hypoxic pharmacological stabilisation of Hypoxia Inducible Factor 1α: effects on dopaminergic differentiation of human neural stem cells” by Morten Meyer and colleagues.
  19. Engineering synucleinopathy‐resistant human dopaminergic neurons by CRISPR‐mediated deletion of the SNCA gene” by Tilo Kunath and colleagues.
  20. Mitochondrial dysfunction and oxidative stress in induced pluripotent stem cell models of Parkinson’s disease” by Anindita Bose and  Flint Beal.
  21. Genetically engineered animal models of Parkinson’s disease: from worm to rodent” by Ludivine Breger and Marie-Thérèse Fuzzati-Armentero.
  22. Induced pluripotent stem cell-based modeling of mutant LRRK2-associated Parkinson’s Disease” by Andreas Till, Oliver Brüstle and colleagues.

Welcome to our new President and Board Members!

Welcome to our new President and Board Members!

At the most recent NECTAR Board Meeting at the NECTAR2018 meeting in Paris, NECTAR welcomed its new President Dr Agnete Kirkeby from Copenhagen University. We also welcomed three new NECTAR Board members, Dr Romina Aron-Badin from CEA Paris, Dr Stefano Pluchino from the University of Cambridge and Dr Rebecca Matsas from Hellenic Pasteur Institute. Welcome everyone and wishing you the very best in your new role Agnete!

Update on Tom Isaacs EJN Special Issue

Update on Tom Isaacs EJN Special Issue

We are delighted to let you know that several articles for the European Journal of Neuroscience, NECTAR and the Cure Parkinson’s Trust Special Issue dedicated to Tom Isaacs have now been published (online ahead of print) and many more are in various stages of review. Those published include:

  1. ***NEW*** “Genetically engineered animal models of Parkinson’s disease: from worm to rodent” by Ludivine Breger and Marie-Thérèse Fuzzati-Armentero.
  2. ***NEW***In Memory of Tom Isaacs: The Epitomical Mover and Shaker” by Lyndsey Isaacs, Roger Barker and Eilís Dowd.
  3. ***NEW*** “Immune system responses in Parkinson’s Disease: early and dynamic” by Malú Tansey and Marina Romero-Ramos.
  4. ***NEW*** “The Prodromes of Parkinson’s disease” by Richard Rees, Alastair Noyce and Anette Schrag.
  5. ***NEW*** Mitochondrial dysfunction and oxidative stress in induced pluripotent stem cell models of Parkinson’s disease” by Anindita Bose and M. Flint Beal.
  6. ***NEW***Engineering synucleinopathy‐resistant human dopaminergic neurons by CRISPR‐mediated deletion of the SNCA gene” by Tilo Kunath and colleagues.
  7. ***NEW*** “Non-hypoxic pharmacological stabilisation of Hypoxia Inducible Factor 1α: effects on dopaminergic differentiation of human neural stem cells” by Morten Meyer and colleagues.
  8. The Power of the Parkinson’s Patient According to Tom Isaacs: A Call to Action” by Soania Mathur.
  9. The Linked Clinical Trials Initiative (LCT) for Parkinson’s disease” by Patrik Brundin and Richard Wyse.
  10. “The clinical heterogeneity of Parkinson’s disease and its therapeutic implications” by Julia Greenland, Caroline Williams‐Gray and Roger A. Barker.
  11. Post hoc analysis of the Exenatide-PD trial – factors that predict response” by Tom Foltynie and colleagues.
  12. Cell-based therapy for Parkinson’s disease: A journey through decades toward the light side of the Force” by Malin Parmar, Olof Torper and Janelle Drouin‐Ouellet.
  13. The Unlikely Partnership Between LRRK2 and α-Synuclein in Parkinson’s Disease” by Andrew West, Emmanuel Brouillet and colleagues.
  14. Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?” by Susan Fox and Jonathan Brotchie.
  15. Primary tissue for cellular brain repair in Parkinson’s disease: Promise, problems and the potential of biomaterials” by  Niamh Moriarty, Clare Parish and Eilís Dowd.
  16. L-DOPA for Parkinson’s disease – a bittersweet pill” by Emma Lane.
  17. Trophic factors for Parkinson’s disease: Where are we and where do we go from here?” by Gesine Paul and Aideen Sullivan.
  18. Mitral cells and the glucagon-like peptide 1 receptor: The sweet smell of success?” by Enrico Bagnoli and Una Fitzgerald.
  19. Encapsulation of young donor age dopaminergic grafts in a GDNF-loaded collagen hydrogel further increases their survival, reinnervation, and functional efficacy after intrastriatal transplantation in hemi-Parkinsonian rats” by Eilís Dowd and colleagues.

Watch this space for new articles as they appear!

CARE travel bursaries for NECTAR2018

CARE travel bursaries for NECTAR2018

The Campaign for Alzheimer’s Research in Europe (CARE) has offered to sponsor travel bursaries for UK or Irish students or postdocs to attend the 2018 NECTAR meeting, to be held 6-7 December 2018 in Paris.

Applications will be competitive and are open to PhD students and post-docs (but not salaried faculty) from any NECTAR member laboratories within the UK and Ireland, and will be for a max of £350 (UK) or €400 (Ireland) each. The applicant must submit an abstract for a data-blitz or invited oral presentation at the meeting. The subject may be in any area of neurorestoration or transplantation for neurodegenerative disease, although applications that focus on Alzheimer’s disease and dementia are particularly welcomed.

Applications should be submitted by email to alzheimerscare1@outlook.com and comprise the following attachments:

  1. a 1-page CV;
  2. a copy of the abstract;
  3. a statement of estimated costs claimed, which may cover, travel, registration and accommodation, along with a declaration that these costs cannot be met from any other source;
  4. a supporting letter from the head of laboratory.

The deadline for applications is 12 noon GMT Monday 5 November (following closure of the abstract and early registration deadline), and CARE will seek to notify decisions within 7 days following.